We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+16.35%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$239M
AUM Growth
-$103M
(-30%)
Cap. Flow
-$106M
Cap. Flow
% of AUM
-44.2%
Top 10 Holdings %
Top 10 Hldgs %
35.32%
Holding
114
New
39
Increased
6
Reduced
19
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$3.8M |
| 2 |
HCA Healthcare
HCA
|
+$3.62M |
| 3 |
HOLX
Hologic
HOLX
|
+$3.59M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$3.47M |
| 5 |
Medtronic
MDT
|
+$3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$9.9M |
| 2 |
Centene
CNC
|
+$7.74M |
| 3 |
AGN
Allergan plc
AGN
|
+$7.17M |
| 4 |
DexCom
DXCM
|
+$6.24M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$6.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.43% |
| 2 | Industrials | 2.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
OSI Systems
OSIS
$3.53B
| $13M | 5.43% |
+201,500
| New | +$16.9M |
|
2
CALL
LivaNova
LIVN
$4.47B
| $10.2M | 4.28% |
+128,000
| New | +$10.2M |
|
3
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.05B
| $9.07M | 3.8% |
130,000
+80,000
| +160% | +$5.46M |
|
4
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
| $8.27M | 3.46% |
100,000
| – | – |
|
5
ICU Medical
ICUI
$4.16B
| $7.56M | 3.16% |
35,000
-22,500
| -39% | -$4.55M |
|
6
Globus Medical
GMED
$11.1B
| $7.5M | 3.14% |
182,500
+53,426
| +41% | +$1.87M |
|
7
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
| $7.43M | 3.11% |
87,500
+37,500
| +75% | +$3.14M |
|
8
PUT
iShares Russell 2000 ETF
IWM
$79.1B
| $7.24M | 3.03% |
47,500
+7,500
| +19% | +$1.13M |
|
|
9
LivaNova
LIVN
$4.47B
| $7.19M | 3.01% |
90,000
-64,273
| -42% | -$5.1M |
|
10
PUT
iShares Biotechnology ETF
IBB
$9.45B
| $6.94M | 2.9% |
65,000
+35,000
| +117% | +$3.74M |
|
|
ATHN
11
DELISTED
Athenahealth, Inc.
ATHN
| $6.65M | 2.78% |
50,000
-9,800
| -16% | -$1.25M |
|
12
Dentsply Sirona
XRAY
$2.84B
| $6.09M | 2.55% |
92,500
-67,500
| -42% | -$4.29M |
|
13
Boston Scientific
BSX
$68.4B
| $5.7M | 2.39% |
230,000
-160,000
| -41% | -$4.41M |
|
|
14
PUT
Boston Scientific
BSX
$68.4B
| $5.7M | 2.39% |
+230,000
| New | +$6.34M |
|
|
ZGNX
15
DELISTED
Zogenix, Inc.
ZGNX
| $5.22M | 2.18% |
130,268
+90,268
| +226% | +$3.47M |
|
|
MZOR
16
PUT
DELISTED
Mazor Robotics Ltd.
MZOR
| $4.76M | 1.99% |
+92,300
| New | +$5.19M |
|
17
PUT
Incyte
INCY
$25.8B
| $4.74M | 1.98% |
50,000
| – | – |
|
|
WBA
18
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $4.72M | 1.97% |
65,000
-5,000
| -7% | -$352K |
|
|
IVC
19
DELISTED
Invacare Corporation
IVC
| $4.67M | 1.95% |
277,274
-222,726
| -45% | -$3.62M |
|
20
Abbott
ABT
$187B
| $4.57M | 1.91% |
80,000
| – | – |
|
21
PUT
Vanda Pharmaceuticals
VNDA
$304M
| $4.56M | 1.91% |
+300,000
| New | +$4.45M |
|
22
Baxter International
BAX
$12.8B
| $4.53M | 1.89% |
70,000
-65,000
| -48% | -$4.17M |
|
|
23
HCA Healthcare
HCA
$88.4B
| $3.95M | 1.65% |
+45,000
| New | +$3.62M |
|
|
24
BioMarin Pharmaceuticals
BMRN
$11.9B
| $3.9M | 1.63% |
+43,700
| New | +$3.8M |
|
|
HOLX
25
DELISTED
Hologic
HOLX
| $3.85M | 1.61% |
+90,000
| New | +$3.59M |
|
Similar funds
GMP
BCA
ONGA
RC
CVV
DOFI
SRA
SR
Pura Vida Investments's Q4 2017 Portfolio in Review
As of Q4 2017, Pura Vida Investments held 114 positions worth $239M, down 30% from $342M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Pura Vida Investments withdrew a net $106M in Q4 2017, closing 45 positions and reducing 19 holdings. Its most notable exit was Merck, an estimated $9.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 50% a quarter earlier, followed by Industrials.
Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $3.9M.
- Pura Vida Investments's largest Q4 2017 buy was BioMarin Pharmaceuticals: 43,700 shares worth $3.9M.
- Pura Vida Investments added most to Zogenix, Inc. in Q4 2017, an estimated $3.47M increase.
- Pura Vida Investments's biggest Q4 2017 reduction was LivaNova, cutting an estimated $5.1M.
- Pura Vida Investments fully exited Merck in Q4 2017, selling an estimated $9.9M.
- Pura Vida Investments's ten largest holdings make up 35% of its $239M portfolio in Q4 2017.
- Pura Vida Investments opened 39 new positions and closed 45 in Q4 2017.
- Pura Vida Investments's portfolio value fell 30% quarter-over-quarter to $239M.
Based on Pura Vida Investments's 13F filing for Q4 2017, filed 14 Feb 2018.